SCHEMBL3972913

SCHEMBL3972913

COc1c(C=CC(=O)c2ccc(SC)cc2)c(C)c(C)c(C(=O)O)c1C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
LMNA P02545 4/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 3/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
NPC1 O15118 1/20 0.40
NFKB1 P19838 1/20 0.40
HTT P42858 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3968383 0.87 MAOA (0.47) LMNAMAPTMEN1KMT2ACYP1A1
SCHEMBL3972915 0.75 DAO (0.38) MAPTMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL498781 0.75 PPARG (0.51) PPARGPPARDPPARALMNAMAPT
SCHEMBL29214717 0.74 CYP1A1 (0.55) CYP1A1CYP1B1
SCHEMBL29214712 0.73 PPARG (0.47) PPARGPPARDPPARALMNAMAPT
SCHEMBL19252965 0.69 PPARG (0.55) PPARGPPARDPPARALMNAMAPT
SCHEMBL499186 0.69 ABCB1 (0.53) LMNAMAPTMEN1ALDH1A1KMT2A
SCHEMBL28608357 0.69 PPARG (0.70) PPARGPPARDPPARALMNAMAPT
SCHEMBL30496177 0.69 MAPT (0.42) PPARGPPARDPPARALMNAMAPT
SCHEMBL9337873 0.68 ABCG2 (0.80) LMNAMAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US claimed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US claimed
US-7566737-B2 Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2009-07-28 US disclosed
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients GENFIT (FR) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032543-A1 Combinations of substituted 1,3-diphenylprop-2-EN-1-one derivatives with other therapeutically active ingredients PSEN1, BACE1, PSEN2 PPARG 17/4885PPARD 39/4885PPARA 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.